Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world

• Published in: Alimentary pharmacology & therapeutics 2022-09, Vol.56 (6), p.942-956
• Main Authors: Henry, Linda, Paik, James, Younossi, Zobair M.
• Format: Article
• Language: English
• Subjects: Comorbidity; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - epidemiology; Epidemiology; Fatty liver; Female; Fibrosis; Health care; Humans; Incidence; Liver diseases; Male; Menopause; Metabolic syndrome; Metabolic Syndrome - complications; Metabolic Syndrome - epidemiology; Morbidity; Mortality; Non-alcoholic Fatty Liver Disease - epidemiology; Non-alcoholic Fatty Liver Disease - etiology; Obesity; Obesity - epidemiology; Patients; Prevalence; Public health; Subpopulations
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1111/apt.17158

Summary Background The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing in parallel with obesity and type 2 diabetes. Aim To review the global epidemiology of NAFLD Methods We retrieved articles from PubMed using search terms of NAFLD, epidemiology, prevalence, incidence, and comorbidities. Results Over 250 articles were reviewed. In 2016, the global NAFLD prevalence was 25%; this increased to >30% in 2019. Prevalence in Asia, Latin America and Middle East‐North Africa (MENA) was 30.8%, 34.5% and 42.6%, respectively. Prevalence increased with age. Although prevalence was higher in men, prevalence in post‐menopausal women was similar. NAFLD prevalence was higher in certain subpopulations, especially among the obese and those with metabolic syndrome (MS). However, the prevalence of lean NAFLD was 11.2%. The global prevalence of non‐alcoholic steatohepatitis (NASH) is estimated between 2% and 6% in the general population. Approximately 7% of patients with NAFLD have advanced fibrosis; rates were between 21% and 50% among patients with NASH. Overall mortality related to NAFLD was 15–20 per 1000 person‐years, and increased substantially in patients with NASH, especially in those with components of MS. Recent data suggest mortality/morbidity from NAFLD is increasing globally but NAFLD awareness remains low among patients and healthcare providers. Conclusions NAFLD poses a global public health problem with a very high disease burden in Asia, MENA and Latin America. Research is needed to better quantify the full impact of NAFLD and to develop strategies to improve awareness and risk stratification. xxxx